Sign In

Login

Password

Forgot Password ? Sign Up

Bilastin (Croatian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Bilastin" in Croatian language version.

refsWebsite
Global rank Croatian rank
18nih.gov
4th place
13th place
17doi.org
2nd place
12th place
14semanticscholar.org
11th place
532nd place
5web.archive.org
1st place
1st place
2tga.gov.au
3,984th place
low place
1hemed.hr
low place
low place
1medicines.org.uk
3,823rd place
low place
1mimsonline.com.au
low place
low place
1drugs.com
399th place
3,120th place
1hikma.com
low place
low place

doi.org (Global: 2nd place; Croatian: 12th place)

drugs.com (Global: 399th place; Croatian: 3,120th place)

hemed.hr (Global: low place; Croatian: low place)

hikma.com (Global: low place; Croatian: low place)

medicines.org.uk (Global: 3,823rd place; Croatian: low place)

mimsonline.com.au (Global: low place; Croatian: low place)

nih.gov (Global: 4th place; Croatian: 13th place)

pubmed.ncbi.nlm.nih.gov

  • Corcóstegui R, Labeaga L, Innerárity A, Berisa A, Orjales A. 2005. Preclinical pharmacology of bilastine, a new selective histamine H1 receptor antagonist: receptor selectivity and in vitro antihistaminic activity. Drugs in R&D. 6 (6): 371–384. doi:10.2165/00126839-200506060-00005. PMID 16274260. S2CID 23407135
  • Jáuregui I, Bartra J, del Cuvillo A, Dávila I, Ferrer M, Montoro J, Mullol J, Sastre J, Valero A. 2011. Bilastine and quality of life. Journal of Investigational Allergology & Clinical Immunology. 21 (Suppl 3): 16–23. PMID 22185046
  • Ding HX, Liu KK, Sakya SM, Flick AC, O'Donnell CJ. Lipanj 2013. Synthetic approaches to the 2011 new drugs. Bioorganic & Medicinal Chemistry. 21 (11): 2795–2825. doi:10.1016/j.bmc.2013.02.061. PMID 23623674
  • Church MK, Tiongco-Recto M, Ridolo E, Novák Z. Ožujak 2020. Bilastine: a lifetime companion for the treatment of allergies. Current Medical Research and Opinion. 36 (3): 445–454. doi:10.1080/03007995.2019.1681134. PMID 31612732
  • Bousquet J, Ansótegui I, Canonica GW, Zuberbier T, Baena-Cagnani CE, Bachert C, Cruz AA, González SN, Kuna P, Morais-Almeida M, Mullol J, Ryan DP, Sánchez-Borges M, Valiente R, Church MK. Siječanj 2012. Establishing the place in therapy of bilastine in the treatment of allergic rhinitis according to ARIA: evidence review. Current Medical Research and Opinion. 28 (1): 131–139. doi:10.1185/03007995.2011.648263. PMID 22149770. S2CID 8429174
  • Bachert C, Kuna P, Sanquer F, Ivan P, Dimitrov V, Gorina MM, van de Heyning P, Loureiro A, i dr. (Bilastine International Working Group). Siječanj 2009. Comparison of the efficacy and safety of bilastine 20 mg vs desloratadine 5 mg in seasonal allergic rhinitis patients. Allergy. 64 (1): 158–165. doi:10.1111/j.1398-9995.2008.01813.x. PMID 19132976. S2CID 20109223
  • Church MK, Labeaga L. Rujan 2017. Bilastine: a new H1 -antihistamine with an optimal profile for updosing in urticaria. Journal of the European Academy of Dermatology and Venereology. 31 (9): 1447–1452. doi:10.1111/jdv.14305. PMID 28467671. S2CID 35712759
  • Horak F, Zieglmayer P, Zieglmayer R, Lemell P. Svibanj 2010. The effects of bilastine compared with cetirizine, fexofenadine, and placebo on allergen-induced nasal and ocular symptoms in patients exposed to aeroallergen in the Vienna Challenge Chamber. Inflammation Research. 59 (5): 391–398. doi:10.1007/s00011-009-0117-4. PMID 19943178. S2CID 30289994
  • Kuna P, Bachert C, Nowacki Z, van Cauwenberge P, Agache I, Fouquert L, Roger A, Sologuren A, Valiente R, i dr. (Bilastine International Working Group). Rujan 2009. Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo for the symptomatic treatment of seasonal allergic rhinitis: a randomized, double-blind, parallel-group study. Clinical and Experimental Allergy. 39 (9): 1338–1347. doi:10.1111/j.1365-2222.2009.03257.x. PMID 19438584. S2CID 42461412
  • Zuberbier T, Oanta A, Bogacka E, Medina I, Wesel F, Uhl P, Antépara I, Jáuregui I, Valiente R. Travanj 2010. Comparison of the efficacy and safety of bilastine 20 mg vs levocetirizine 5 mg for the treatment of chronic idiopathic urticaria: a multi-centre, double-blind, randomized, placebo-controlled study. Allergy. 65 (4): 516–528. doi:10.1111/j.1398-9995.2009.02217.x. PMID 19860762. S2CID 24312427
  • Tyl B, Kabbaj M, Azzam S, Sologuren A, Valiente R, Reinbolt E, Roupe K, Blanco N, Wheeler W. Lipanj 2012. Lack of significant effect of bilastine administered at therapeutic and supratherapeutic doses and concomitantly with ketoconazole on ventricular repolarization: results of a thorough QT study (TQTS) with QT-concentration analysis. Journal of Clinical Pharmacology. 52 (6): 893–903. doi:10.1177/0091270011407191. PMID 21642470. S2CID 11649589
  • Graff C, Struijk JJ, Kanters JK, Andersen MP, Toft E, Tyl B. Svibanj 2012. Effects of bilastine on T-wave morphology and the QTc interval: a randomized, double-blind, placebo-controlled, thorough QTc study. Clinical Drug Investigation. 32 (5): 339–351. doi:10.2165/11599270-000000000-00000. PMID 22393898. S2CID 22766684
  • Bailey DG. Studeni 2010. Fruit juice inhibition of uptake transport: a new type of food-drug interaction. British Journal of Clinical Pharmacology. 70 (5): 645–655. doi:10.1111/j.1365-2125.2010.03722.x. PMC 2997304. PMID 21039758
  • Corcóstegui R, Labeaga L, Innerárity A, Berisa A, Orjales A. 2005. Preclinical pharmacology of bilastine, a new selective histamine H1 receptor antagonist: receptor selectivity and in vitro antihistaminic activity. Drugs in R&D. 6 (6): 371–384. doi:10.2165/00126839-200506060-00005. PMID 16274260. S2CID 23407135
  • Jáuregui I, García-Lirio E, Soriano AM, Gamboa PM, Antépara I. Siječanj 2012. An overview of the novel H1-antihistamine bilastine in allergic rhinitis and urticaria. Expert Review of Clinical Immunology. 8 (1): 33–41. doi:10.1586/eci.11.87. PMID 22149338. S2CID 207209051
  • Jauregizar N, de la Fuente L, Lucero ML, Sologuren A, Leal N, Rodríguez M. 1. kolovoza 2009. Pharmacokinetic-pharmacodynamic modelling of the antihistaminic (H1) effect of bilastine. Clinical Pharmacokinetics. 48 (8): 543–554. doi:10.2165/11317180-000000000-00000. PMID 19705924. S2CID 552051
  • Montoro J, Mullol J, Dávila I, Ferrer M, Sastre J, Bartra J, Jáuregui I, del Cuvillo A, Valero A. 2011. Bilastine and the central nervous system. Journal of Investigational Allergology & Clinical Immunology. 21 (Suppl 3): 9–15. PMID 22185045

ncbi.nlm.nih.gov

semanticscholar.org (Global: 11th place; Croatian: 532nd place)

api.semanticscholar.org

  • Corcóstegui R, Labeaga L, Innerárity A, Berisa A, Orjales A. 2005. Preclinical pharmacology of bilastine, a new selective histamine H1 receptor antagonist: receptor selectivity and in vitro antihistaminic activity. Drugs in R&D. 6 (6): 371–384. doi:10.2165/00126839-200506060-00005. PMID 16274260. S2CID 23407135
  • Bousquet J, Ansótegui I, Canonica GW, Zuberbier T, Baena-Cagnani CE, Bachert C, Cruz AA, González SN, Kuna P, Morais-Almeida M, Mullol J, Ryan DP, Sánchez-Borges M, Valiente R, Church MK. Siječanj 2012. Establishing the place in therapy of bilastine in the treatment of allergic rhinitis according to ARIA: evidence review. Current Medical Research and Opinion. 28 (1): 131–139. doi:10.1185/03007995.2011.648263. PMID 22149770. S2CID 8429174
  • Bachert C, Kuna P, Sanquer F, Ivan P, Dimitrov V, Gorina MM, van de Heyning P, Loureiro A, i dr. (Bilastine International Working Group). Siječanj 2009. Comparison of the efficacy and safety of bilastine 20 mg vs desloratadine 5 mg in seasonal allergic rhinitis patients. Allergy. 64 (1): 158–165. doi:10.1111/j.1398-9995.2008.01813.x. PMID 19132976. S2CID 20109223
  • Church MK, Labeaga L. Rujan 2017. Bilastine: a new H1 -antihistamine with an optimal profile for updosing in urticaria. Journal of the European Academy of Dermatology and Venereology. 31 (9): 1447–1452. doi:10.1111/jdv.14305. PMID 28467671. S2CID 35712759
  • Horak F, Zieglmayer P, Zieglmayer R, Lemell P. Svibanj 2010. The effects of bilastine compared with cetirizine, fexofenadine, and placebo on allergen-induced nasal and ocular symptoms in patients exposed to aeroallergen in the Vienna Challenge Chamber. Inflammation Research. 59 (5): 391–398. doi:10.1007/s00011-009-0117-4. PMID 19943178. S2CID 30289994
  • Kuna P, Bachert C, Nowacki Z, van Cauwenberge P, Agache I, Fouquert L, Roger A, Sologuren A, Valiente R, i dr. (Bilastine International Working Group). Rujan 2009. Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo for the symptomatic treatment of seasonal allergic rhinitis: a randomized, double-blind, parallel-group study. Clinical and Experimental Allergy. 39 (9): 1338–1347. doi:10.1111/j.1365-2222.2009.03257.x. PMID 19438584. S2CID 42461412
  • Zuberbier T, Oanta A, Bogacka E, Medina I, Wesel F, Uhl P, Antépara I, Jáuregui I, Valiente R. Travanj 2010. Comparison of the efficacy and safety of bilastine 20 mg vs levocetirizine 5 mg for the treatment of chronic idiopathic urticaria: a multi-centre, double-blind, randomized, placebo-controlled study. Allergy. 65 (4): 516–528. doi:10.1111/j.1398-9995.2009.02217.x. PMID 19860762. S2CID 24312427
  • Tyl B, Kabbaj M, Azzam S, Sologuren A, Valiente R, Reinbolt E, Roupe K, Blanco N, Wheeler W. Lipanj 2012. Lack of significant effect of bilastine administered at therapeutic and supratherapeutic doses and concomitantly with ketoconazole on ventricular repolarization: results of a thorough QT study (TQTS) with QT-concentration analysis. Journal of Clinical Pharmacology. 52 (6): 893–903. doi:10.1177/0091270011407191. PMID 21642470. S2CID 11649589
  • Graff C, Struijk JJ, Kanters JK, Andersen MP, Toft E, Tyl B. Svibanj 2012. Effects of bilastine on T-wave morphology and the QTc interval: a randomized, double-blind, placebo-controlled, thorough QTc study. Clinical Drug Investigation. 32 (5): 339–351. doi:10.2165/11599270-000000000-00000. PMID 22393898. S2CID 22766684
  • Bachert C, Kuna P, Zuberbier T. 1. lipnja 2010. Bilastine in allergic rhinoconjunctivitis and urticaria. Allergy. 65: 1–13. doi:10.1111/j.1398-9995.2010.02404.x. S2CID 52228628
  • Corcóstegui R, Labeaga L, Innerárity A, Berisa A, Orjales A. 2005. Preclinical pharmacology of bilastine, a new selective histamine H1 receptor antagonist: receptor selectivity and in vitro antihistaminic activity. Drugs in R&D. 6 (6): 371–384. doi:10.2165/00126839-200506060-00005. PMID 16274260. S2CID 23407135
  • Jáuregui I, García-Lirio E, Soriano AM, Gamboa PM, Antépara I. Siječanj 2012. An overview of the novel H1-antihistamine bilastine in allergic rhinitis and urticaria. Expert Review of Clinical Immunology. 8 (1): 33–41. doi:10.1586/eci.11.87. PMID 22149338. S2CID 207209051
  • Jauregizar N, de la Fuente L, Lucero ML, Sologuren A, Leal N, Rodríguez M. 1. kolovoza 2009. Pharmacokinetic-pharmacodynamic modelling of the antihistaminic (H1) effect of bilastine. Clinical Pharmacokinetics. 48 (8): 543–554. doi:10.2165/11317180-000000000-00000. PMID 19705924. S2CID 552051
  • Church MK. 2021. Antihistamines. Urticaria and Angioedema. Springer International Publishing. str. 153–165. doi:10.1007/978-3-030-84574-2_11. ISBN 978-3-030-84573-5. S2CID 239944965

tga.gov.au (Global: 3,984th place; Croatian: low place)

ebs.tga.gov.au

  • Australian Product Information - Allertine (Bilastine) tablet. Therapeutic Goods Administration. 27. travnja 2022. Inačica izvorne stranice arhivirana 13. rujna 2022. Pristupljeno 13. rujna 2022.

tga.gov.au

web.archive.org (Global: 1st place; Croatian: 1st place)

  • Australian Product Information - Allertine (Bilastine) tablet. Therapeutic Goods Administration. 27. travnja 2022. Inačica izvorne stranice arhivirana 13. rujna 2022. Pristupljeno 13. rujna 2022.
  • Updates to the Prescribing Medicines in Pregnancy database. Therapeutic Goods Administration (TGA). 21. prosinca 2022. Inačica izvorne stranice arhivirana 3. travnja 2022. Pristupljeno 2. siječnja 2023.
  • Ilaxten 20 mg tablets - Summary of Product Characteristics (SmPC). (emc). Inačica izvorne stranice arhivirana 24. lipnja 2021. Pristupljeno 16. lipnja 2021.
  • Allertine (bilastine). MIMS. Inačica izvorne stranice arhivirana 28. studenoga 2023. Pristupljeno 13. rujna 2022.
  • Bilastine Approval Status  Arhivirana inačica izvorne stranice od 27. kolovoza 2023. (Wayback Machine), drugs.com